As of Mar 02
| 0.00 / 0.00%|
The 2 analysts offering 12-month price forecasts for Cancer Genetics Inc have a median target of 16.50, with a high estimate of 20.00 and a low estimate of 13.00. The median estimate represents a +88.36% increase from the last price of 8.76.
The current consensus among 2 polled investment analysts is to Buy stock in Cancer Genetics Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.